A detailed history of Schonfeld Strategic Advisors LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 22,738 shares of ALT stock, worth $153,254. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,738
Previous 101,426 77.58%
Holding current value
$153,254
Previous $1.03 Million 85.37%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$5.91 - $10.23 $465,046 - $804,978
-78,688 Reduced 77.58%
22,738 $151,000
Q1 2024

May 15, 2024

SELL
$8.22 - $13.81 $275,978 - $463,656
-33,574 Reduced 24.87%
101,426 $1.03 Million
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $288,900 - $1.57 Million
135,000 New
135,000 $1.52 Million
Q2 2023

Aug 14, 2023

SELL
$3.45 - $5.97 $711,876 - $1.23 Million
-206,341 Reduced 75.19%
68,100 $240,000
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $1.15 Million - $4.62 Million
274,441 New
274,441 $1.16 Million
Q3 2022

Nov 14, 2022

SELL
$10.67 - $22.41 $1.29 Million - $2.71 Million
-120,898 Reduced 67.54%
58,102 $742,000
Q2 2022

Aug 15, 2022

BUY
$3.94 - $11.77 $640,250 - $1.91 Million
162,500 Added 984.85%
179,000 $2.09 Million
Q1 2022

May 16, 2022

SELL
$5.9 - $9.45 $8,260 - $13,229
-1,400 Reduced 7.82%
16,500 $101,000
Q4 2021

Feb 14, 2022

SELL
$8.69 - $12.48 $423,203 - $607,776
-48,700 Reduced 73.12%
17,900 $164,000
Q3 2021

Nov 16, 2021

BUY
$8.43 - $16.81 $561,438 - $1.12 Million
66,600 New
66,600 $754,000
Q2 2021

Aug 16, 2021

SELL
$9.85 - $16.46 $983,364 - $1.64 Million
-99,834 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$12.71 - $24.31 $1.27 Million - $2.43 Million
99,834 New
99,834 $1.41 Million
Q3 2020

Nov 16, 2020

SELL
$9.93 - $33.26 $346,557 - $1.16 Million
-34,900 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$2.9 - $10.71 $101,210 - $373,779
34,900 New
34,900 $374,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $330M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.